[go: up one dir, main page]

UY31631A1 - Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones - Google Patents

Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones

Info

Publication number
UY31631A1
UY31631A1 UY031631A UY31631A UY31631A1 UY 31631 A1 UY31631 A1 UY 31631A1 UY 031631 A UY031631 A UY 031631A UY 31631 A UY31631 A UY 31631A UY 31631 A1 UY31631 A1 UY 31631A1
Authority
UY
Uruguay
Prior art keywords
salts
processes
preparation
phenil
pirimidin
Prior art date
Application number
UY031631A
Other languages
English (en)
Inventor
Philipp Holzer
Christoph Gaul
Carole Pissot
Marc Gerspacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31631A1 publication Critical patent/UY31631A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a los compuestos de la fórmula I, y sales de los mismos: en donde los sustituyentes son como se definen en la memoria descriptiva, a procesos para la preparación de los mismos; a productos farmacéuticos que contienen tales compuestos, en particular para el uso en una o más enfermedades mediadas por la cinasa de proteína tirosina.
UY031631A 2008-02-06 2009-02-04 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones UY31631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08151137 2008-02-06

Publications (1)

Publication Number Publication Date
UY31631A1 true UY31631A1 (es) 2009-09-30

Family

ID=39739330

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031631A UY31631A1 (es) 2008-02-06 2009-02-04 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones

Country Status (27)

Country Link
US (1) US8420657B2 (es)
EP (1) EP2247591A1 (es)
JP (1) JP5323095B2 (es)
KR (2) KR101277823B1 (es)
CN (1) CN101981036B (es)
AR (1) AR070558A1 (es)
AU (1) AU2009211338B2 (es)
BR (1) BRPI0908433A2 (es)
CA (1) CA2714177A1 (es)
CL (1) CL2009000255A1 (es)
CO (1) CO6321262A2 (es)
CR (1) CR11614A (es)
DO (1) DOP2010000242A (es)
EA (1) EA017952B1 (es)
EC (1) ECSP10010463A (es)
IL (1) IL207224A0 (es)
MA (1) MA32134B1 (es)
MX (1) MX2010008719A (es)
NI (1) NI201000137A (es)
NZ (1) NZ587271A (es)
PA (1) PA8815201A1 (es)
PE (1) PE20091485A1 (es)
SM (1) SMP201000104B (es)
TW (1) TW200938202A (es)
UY (1) UY31631A1 (es)
WO (1) WO2009098236A1 (es)
ZA (1) ZA201005338B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CN102014959B (zh) * 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
PL2331547T3 (pl) * 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
CN106986875A (zh) * 2009-04-23 2017-07-28 Abbvie 公司 5‑ht受体的调节剂和其使用方法
MX2012004020A (es) * 2009-10-20 2012-05-08 Cellzome Ltd Analogos de heterociclilo pirazolopirimidina como inhibidores de jak.
WO2011068881A1 (en) * 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US20130131043A1 (en) 2010-04-30 2013-05-23 Richard John Harrison Pyrazole compounds as jak inhibitors
US9586961B2 (en) 2010-07-09 2017-03-07 Leo Pharma A/S Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
JP2013540748A (ja) * 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
JP5832647B2 (ja) 2011-07-01 2015-12-16 ノバルティス アーゲー がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
AU2012311504B2 (en) 2011-09-20 2016-03-24 Cellzome Limited Pyrazolo[4,3-C]pyridine derivatives as kinase inhibitors
KR20140091695A (ko) * 2011-11-15 2014-07-22 노파르티스 아게 포스포이노시티드 3-키나제 억제제와 야누스 키나제 2-신호 전달자 및 전사 활성화제 5 경로의 조절제의 조합물
CN102627646A (zh) * 2012-03-19 2012-08-08 苏州四同医药科技有限公司 一种3-碘-5-溴-4,7-二氮杂吲哚的制备方法
CN102633802B (zh) * 2012-04-11 2014-03-19 南京药石药物研发有限公司 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法
CN106008511B (zh) * 2012-05-14 2018-08-14 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
CN103059030B (zh) * 2012-12-28 2015-04-29 北京师范大学 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
KR102139847B1 (ko) * 2014-05-01 2020-07-31 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
ES2908150T3 (es) * 2014-05-01 2022-04-27 Novartis Ag Compuestos y composiciones como agonistas del receptor de tipo Toll 7
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP4424328A3 (en) 2018-03-30 2024-12-04 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
CN111484496B (zh) * 2019-01-29 2022-11-29 江苏开元药业有限公司 2-氨基-吡咯并嘧啶和吡唑并嘧啶类化合物及其制备方法和用途
MX2021013602A (es) 2019-05-08 2022-04-06 Vimalan Biosciences Inc Inhibidores de jak.
CN110305140B (zh) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
TW202122400A (zh) 2019-08-08 2021-06-16 美商維瑪蘭生物科學公司 Jak抑制劑
GB201911868D0 (en) * 2019-08-19 2019-10-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2021050700A1 (en) * 2019-09-13 2021-03-18 The Broad Institute, Inc. Cyclooxygenase-2 inhibitors and uses thereof
GB201914910D0 (en) * 2019-10-15 2019-11-27 Sentinel Oncology Ltd Pharmaceutical compounds
CN117043163A (zh) * 2021-09-08 2023-11-10 希格生科（深圳）有限公司 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
CN116813624B (zh) * 2023-06-29 2025-10-03 成都金瑞基业生物科技有限公司 一种jak2抑制剂的晶型及制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7917643B2 (en) * 1996-09-12 2011-03-29 Audible, Inc. Digital information library and delivery system
US20030074530A1 (en) * 1997-12-11 2003-04-17 Rupaka Mahalingaiah Load/store unit with fast memory data access mechanism
US6887224B2 (en) * 1998-06-15 2005-05-03 Ilse Rubio Close fitting leakage resistant feminine hygiene pad
HRP20000885B1 (hr) 1998-06-19 2007-03-31 Pfizer Products Inc. PIROLO[2,3-d]PIRIMIDINSKI SPOJEVI
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
MXPA04008592A (es) 2002-03-07 2004-12-06 Hoffmann La Roche Inhibidores de piridina biciclica y pirimidina p38 cinasa.
US7132221B2 (en) * 2003-09-12 2006-11-07 Headway Technologies, Inc. Method to print photoresist lines with negative sidewalls
US7532909B2 (en) * 2003-10-15 2009-05-12 Nextel Communications Inc. System and method for providing dedicated paging channels for walkie-talkie services
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
DK1713806T3 (da) * 2004-02-14 2013-08-05 Irm Llc Forbindelser og sammensætninger som proteinkinaseinhibitorer
JP2007526906A (ja) 2004-03-05 2007-09-20 大正製薬株式会社 ピロロピリミジン誘導体
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
MX2007005159A (es) * 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
US20060122003A1 (en) * 2004-12-03 2006-06-08 Kim Jong H Portable golf swing position training aid kit
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
DE602006004844D1 (de) * 2005-02-03 2009-03-05 Vertex Pharma Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
CA2607021C (en) 2005-05-05 2013-10-29 Ardea Biosciences, Inc. Diaryl-purines, -azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
US7749527B2 (en) 2005-05-24 2010-07-06 Wyeth Llc Gel compositions for control of ecto-parasites
JP2009511528A (ja) 2005-10-13 2009-03-19 グラクソ グループ リミテッド Ｓｙｋ阻害物質としてのピロロピリミジン誘導体群
RS51843B (sr) 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. KONDENZOVANI BICIKLIČNI m TOR INHIBITORI
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
WO2007109362A2 (en) 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
JP4861772B2 (ja) * 2006-08-28 2012-01-25 富士通株式会社 移動体標定プログラム、該プログラムを記録した記録媒体、移動体標定装置、および移動体標定方法
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR20090033605A (ko) * 2007-10-01 2009-04-06 삼성전자주식회사 적층형 반도체 패키지, 그 형성방법 및 이를 구비하는전자장치
WO2009070524A1 (en) 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
US20090192176A1 (en) 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

Also Published As

Publication number Publication date
AU2009211338A1 (en) 2009-08-13
CR11614A (es) 2010-09-06
AR070558A1 (es) 2010-04-21
CA2714177A1 (en) 2009-08-13
SMAP201000104A (it) 2010-11-12
SMP201000104B (it) 2011-09-09
US8420657B2 (en) 2013-04-16
EA017952B1 (ru) 2013-04-30
PE20091485A1 (es) 2009-10-26
MA32134B1 (fr) 2011-03-01
JP5323095B2 (ja) 2013-10-23
ECSP10010463A (es) 2010-10-30
US20090203688A1 (en) 2009-08-13
PA8815201A1 (es) 2009-09-17
ZA201005338B (en) 2011-09-28
CN101981036A (zh) 2011-02-23
WO2009098236A1 (en) 2009-08-13
DOP2010000242A (es) 2010-08-31
MX2010008719A (es) 2010-09-24
KR20100119786A (ko) 2010-11-10
JP2011511034A (ja) 2011-04-07
KR20130066703A (ko) 2013-06-20
IL207224A0 (en) 2010-12-30
AU2009211338B2 (en) 2011-12-15
NZ587271A (en) 2012-03-30
NI201000137A (es) 2011-09-29
EA201001242A1 (ru) 2011-08-30
CO6321262A2 (es) 2011-09-20
KR101277823B1 (ko) 2013-07-15
EP2247591A1 (en) 2010-11-10
CL2009000255A1 (es) 2009-08-14
CN101981036B (zh) 2013-09-04
TW200938202A (en) 2009-09-16
BRPI0908433A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
UY31631A1 (es) Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
UY31838A (es) Derivados de quinoxalin- y quinolin-carboxamida
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
ECSP18090144A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP099327A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
UY29549A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
UY30859A1 (es) Nuevos derivados de 2-anilino-4-heteroarilpirimidinas , su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
CU20140068A7 (es) Triazolopiridinas sustituidas
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
CY1117210T1 (el) Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης
MX2015016429A (es) Moduladores del receptor cxcr7.
UY29468A1 (es) Nuevos derivados de isoindoles, composiciones que los contienen, su preparación y sus utilizaciones farmacéuticas, especialmente como inhibidores de las actividades de la proteína chaperona hsp90.
UY32422A (es) Derivados de 6-(6-sustituido-triazlopiridacina-sulfanil) 5-fluoro-benzotiazololes y 5-fluoro-bencimidazoles : preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met
UY31972A (es) Derivados anticancerosos, su preparación y su aplicación en terapéutica
GT201400044A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180823